Neil W. Gibson, Ph.D.

Chief Scientific Officer, Biologics

Neil Gibson, Ph.D., brings more than 25 years of drug development experience to his role as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies.

Dr. Gibson has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, BioAtla; chief scientific officer, Regulus Therapeutics; chief scientific officer and oncology therapeutic area head, Pfizer Oncology; and chief scientific officer, OSI Pharmaceuticals.  While at Pfizer, Dr. Gibson was also a member of the Pfizer Oncology Business Unit Executive team.

Dr. Gibson has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib.  While at Regulus, Dr. Gibson was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101.  Dr. Gibson has also been involved in the growth of new biotechnology organizations and significant fund raising.  This includes the initial public offering for Regulus Therapeutics, which raised an initial $80.9 million and subsequent follow on financings of about $105 million.  He was also involved in the growth of OSI Pharmaceuticals from 100 full time employees (FTEs) to approximately 750 FTEs and an increased market cap of approximately $150 million to greater than $4 billion.

Dr. Gibson has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Dr. Gibson earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.

in the news

  • COI Can: World Cancer Day

    read more
  • What does COI look for in an investment opportunity?

    read more
  • Looking Back on 2016: A Year of Firsts, Financings, and Fun

    read more